Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099) by Hinchcliff, Emily, MD, MPH, Patel, Ami, MBBS, MPH, Fellman, Bryan, MS, Yuan, Ying, PhD, Chelvanambi, Manoj, PhD, Wargo, Jen, MD, LIU, YAN, MD, Liu, Jinsong, MD, Lee, Sanghoon, PhD, Roszik, Jason, PhD, MBA, Hillman, Robert, MD, PhD, Westin, Shannon, MD, MPH, Sood, Anil, MD, Soliman, Pamela, MD, Frumovitz, Michael, MD, MPH, Shafer, Aaron, MD, Meyer, Larissa, MD, MPH, Fleming, Nicole, MD, Gershenson, David, MD, Vining, David, MD, Ganeshan, Dhakshina, MD, Hwu, Patrick, MD, Lu, Karen, MD, Jazaeri, Amir, MD

Get full text

Randomized phase II trial of durvalumab (anti-PDL1) and tremelimumab (anti-CTLA4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant... by Hinchcliff, Emily, MD, MPH, Patel, Ami, MBBS, MPH, Fellman, Bryan, MS, Westin, Shannon, MD, Sood, Anil, MD, Soliman, Pamela, MD, Shafer, Aaron, MD, Meyer, Larissa, MD MPH, Fleming, Nicole, MD, Bathala, Tharakeswara, MD, Ganeshan, Dhakshina, MD, Hwu, Patrick, MD, Lu, Karen, MD, Jazaeri, Amir, MD

Get full text